NEW YORK (GenomeWeb) – VolitionRx today announced that the University of Bonn in Germany will begin a clinical study to assess VolitionRx's Nucleosomics platform for the diagnosis of lung cancer through a non-invasive blood test.

The study will be conducted as a separate trial in conjunction with the firm's larger 4,000-subject prospective study at University Hospital Bonn, evaluating NuQ assays in the 20 most prevalent cancers.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.